Capricor Therapeutics (CAPR) Misses Q1 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. SPCX
2. LEVI
3. SBUX
4. NVDA
5. GOOGL
6. APLD
7. ORCL
8. USO
9. STZ
10. AAPL

Go back to Capricor Therapeutics (CAPR) Misses Q1 EPS by 8c

Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024 4:05 PM EDT

Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024

Positive Type-B CMC FDA Meeting held in Q1; Company Aligned with FDA on Demonstration of Non-Clinical Comparability, A Major Milestone on Path to CMC Clearance for BLA

Received First Milestone Payment of $10 Million under U.S. Distribution and Commercialization Agreement with Nippon Shinyaku in Q1

Recent FDA Feedback Supports Requests for a Pre-BLA Meeting and Subsequent Rolling BLA Submission at Upcoming Type-B Clinical FDA Meeting... More